GLP-1

GLP-1 receptor agonists are primarily used in clinical practice for the treatment of type 2 diabetes mellitus and obesity management. The available evidence shows several key clinical applications:

Type 2 Diabetes Management

Clinical trial evidence demonstrates GLP-1 receptor agonists' effectiveness in diabetes treatment. A completed Phase 3 trial (NCT00518882) specifically evaluated the addition of liraglutide or exenatide to existing diabetes treatments for improved blood glucose control in patients with type 2 diabetes. This supports the established clinical use of GLP-1 agonists as add-on therapy when first-line treatments are insufficient.

Metabolic Associated Steatotic Liver Disease (MASLD)

Recent evidence suggests expanding applications in liver disease. A 2026 study examined the combination of GLP-1 receptor agonists with SGLT2 inhibitors versus monotherapy in patients with both MASLD and type 2 diabetes, indicating growing clinical interest in using these agents for non-alcoholic fatty liver disease management.

Cardiovascular and Metabolic Benefits

Research indicates potential cardiovascular applications, with studies comparing long-term cardiovascular benefits of GLP-1 therapies against bariatric surgery in patients with type 2 diabetes and obesity. Additionally, emerging research explores the role of metabolite sensing in heart failure with preserved ejection fraction (HFpEF), suggesting potential future applications in cardiovascular disease.

Safety Considerations

Real-world pharmacovigilance data from 2026 provides safety profiles for newer agents like tirzepatide, while studies on novel oral formulations (such as bofanglutide) demonstrate ongoing development of more convenient delivery methods for these therapies.

Disclaimer: This information is for educational purposes only and should not replace personalized medical advice. Consult with healthcare providers for treatment decisions specific to individual circumstances.

The evidence base for GLP-1 applications continues to expand, though more robust clinical trial data would strengthen conclusions about emerging uses beyond established diabetes indications.